The recent pandemic has shown the threat posed by infectious diseases to the general population. Throughout the pandemic, the importance of vaccines, therapeutics, and diagnostics was evident to aid in the management of the COVID-19 outbreak. This is true for any infectious disease where diagnostics is critical to inform a person of their infection status and therapy to aid in the recovery. The use of antibodies in the development of diagnostics and therapeutics was evident with the surge of antibody development projects during the recent pandemic. This Research Topic focuses on the recent development of recombinant antibody technology for infectious diseases.
The role of recombinant antibodies in infectious diseases was clearly described by Roth et al., where they detailed the application of phage display for the development of antibodies against various infectious agents. The review provided a comprehensive view on the technology and its potential applications. Additionally, Spencer et al. discussed the role antibodies play in the HIV prevention. They were eloquent in describing the challenges faced for moving broadly neutralizing antibodies from discovery to clinic. This has always been seen as a major hurdle for any antibody project. The breadth of coverage conferred by antibodies was highlighted with the review by Longoni et al. where they discussed the role antibodies play in protozoan infections.
Moreira et al. provided an account of how phage display is applied to identify monoclonal antibodies for the detection of Listeria monocytogenes. Liu et al. exhibited the potential of phage display to be used for the development of antibodies against chikungunya virus. The work pays homage to the variability of different recombinant antibody formats that can be engineered. The work focused on the stability of domain antibodies against chikungunya. The application of recombinant DNA technology to engineer improved characteristics can also be witness by the publication from Schneider et al. They showed how lyophilized Fc-fused scFv formats can aid in prolonging the shelf life of the antibodies which is very essential for the applications of antibody therapeutics, but also diagnostics, in countries where a constant cold chain for transport and storage cannot be guaranteed.
With the lessons learned from the latest pandemic, it is evident that the role of recombinant antibodies is critical in times of health crisis for the rapid development of diagnostics and therapeutics. Therefore, constant advancements in technology not only for the isolation and identification of monoclonal antibodies against infectious diseases is crucial, but also for the further development of diagnostic approaches as well as preclinical development.
Publisher's Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Statements
Author contributions
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Summary
Keywords
phage display, antibody, infectious disease, therapeutics, diagnostics
Citation
Lim TS, Hust M and Visai L (2022) Editorial: Recent Advances in Recombinant Antibody Therapeutics and Diagnostics for Infectious Diseases. Front. Public Health 10:876889. doi: 10.3389/fpubh.2022.876889
Received
16 February 2022
Accepted
18 February 2022
Published
14 March 2022
Volume
10 - 2022
Edited and reviewed by
Marc Jean Struelens, Université Libre de Bruxelles, Belgium
Updates
Copyright
© 2022 Lim, Hust and Visai.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Theam Soon Lim theamsoon@usm.myMichael Hust m.hust@tu-bs.deLivia Visai livia.visai@unipv.it
This article was submitted to Infectious Diseases - Surveillance, Prevention and Treatment, a section of the journal Frontiers in Public Health
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.